The JULI Registry--Hemp and Cannabis Observational Registry (JULI)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04726254 |
Recruitment Status :
Recruiting
First Posted : January 27, 2021
Last Update Posted : July 19, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Chronic Pain Appetite Disorders Neuropathy Menopausal Syndrome Anxiety Sleep Disturbance Nausea |

Study Type : | Observational [Patient Registry] |
Estimated Enrollment : | 2000 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Target Follow-Up Duration: | 3 Months |
Official Title: | The JUvaLIfe Registry |
Actual Study Start Date : | August 1, 2021 |
Estimated Primary Completion Date : | February 15, 2024 |
Estimated Study Completion Date : | February 15, 2025 |

- Symptom Relief [ Time Frame: 3 months ]Percentage of patients who obtain and report symptom relief, by symptom, condition and cannabis formulation
- Reduction in reliance on Rx medications [ Time Frame: 3 months ]Percentage of patients who report reduction or increase in use of Rx medications
- Reduction in reliance on OTC medications [ Time Frame: 3 months ]Percentage of patients who report reduction or increase in use of Rx medications

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 21 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- 21 years of age or older
- Have requested from and/or decided with their providers to try CBD (hemp-based) or other cannabis products to relieve one or more symptoms related to a medical diagnosis
- Consent to have their health data included in a Registry and participate in PRO (patient reported outcomes) surveys and data collection via a study app.
Exclusion Criteria:
- Patient pregnant
- Unwilling or unable to provide informed consent

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04726254
Contact: Mary Kay K Hardwick, MBA | 5106826256 | mkhardwick@tmebcn.com | |
Contact: Peter Beitsch, MD | 214 350 6672 | pbeitsch@tmebcn.com |
United States, California | |
Precision Cancer Specialists | Recruiting |
Los Gatos, California, United States, 95032 | |
Contact: Rakesh Patel, MD 608-347-3405 medrockpatel@gmail.com | |
Principal Investigator: Rakesh Patel, MD | |
Justin Lo MD | Recruiting |
San Jose, California, United States, 95128 | |
Contact: Justin Lo, MD 408-295-8628 justin@justinlomd.com | |
United States, Tennessee | |
Nashville Breast Center | Recruiting |
Nashville, Tennessee, United States, 37203 | |
Contact: Pat Whitworth, MD 615-620-5535 pwhitworth@tmebcn.com | |
Contact: Kristie Appleton 615-620-5535 | |
United States, Texas | |
Dallas Surgical Group | Recruiting |
Dallas, Texas, United States, 75231 | |
Contact: Peter Beitsch, MD 214-420-8499 pbeitsch@tmebcn.com | |
Principal Investigator: Peter Beitsch, MD |
Other Publications:
Responsible Party: | Juva Life |
ClinicalTrials.gov Identifier: | NCT04726254 |
Other Study ID Numbers: |
JULI1000 |
First Posted: | January 27, 2021 Key Record Dates |
Last Update Posted: | July 19, 2022 |
Last Verified: | July 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Dyssomnias Parasomnias Chronic Pain Feeding and Eating Disorders Pain |
Neurologic Manifestations Sleep Wake Disorders Nervous System Diseases Mental Disorders |